Lyka Labs said that it has entered into out-licensing / technology transfer deal with a US based Generics Company.
The market size of the licensed formulations is approximately USD 1.4 billion, as per IMS MAT March 2017.
The company will be eligible for a royalty on end sales, filing added.
Going forward, the company will continue to explore opportunities to monetize its R&D capabilities in the regulated markets throughout-licensing partnerships.
Meanwhile, shares of the company were trading at Rs 52 apiece, up 2.97 per cent from the previous close at 11:18 hours on BSE.